Blincyto(blinatumomab)
Blincyto (blinatumomab) is an antibody pharmaceutical. Blinatumomab was first approved as Blincyto on 2014-12-03. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. It is known to target B-lymphocyte antigen CD19 and T-cell surface glycoprotein CD3 epsilon chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Blincyto
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| blincyto | Biologic Licensing Application | 2024-12-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lymphoid leukemia | — | D007945 | C91 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
blinatumomab, Blincyto, Amgen Inc. | |||
| 2025-03-29 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9039 | Injection, blinatumomab, 1 microgram |
Clinical
Clinical Trials
132 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 21 | 63 | 18 | 2 | 9 | 99 |
| Lymphoid leukemia | D007945 | — | C91 | 22 | 63 | 17 | 2 | 8 | 97 |
| Leukemia | D007938 | — | C95 | 21 | 65 | 18 | 2 | 5 | 96 |
| Residual neoplasm | D018365 | — | — | 1 | 9 | — | 1 | 2 | 13 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 5 | 9 | — | 1 | — | 13 |
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | 2 | 4 | 1 | 1 | 1 | 7 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Philadelphia chromosome | D010677 | — | — | 4 | 16 | 3 | — | 1 | 22 |
| Lymphoma | D008223 | — | C85.9 | 10 | 10 | 3 | — | — | 19 |
| B-cell lymphoma | D016393 | — | — | 7 | 6 | 1 | — | — | 11 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 6 | 5 | 1 | — | — | 10 |
| Recurrence | D012008 | — | — | 4 | 2 | 1 | — | 1 | 7 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 1 | 4 | 1 | — | — | 4 |
| Hodgkin disease | D006689 | — | C81 | 1 | 3 | 1 | — | — | 3 |
| Acute disease | D000208 | — | — | 2 | — | 1 | — | — | 3 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 1 | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | 1 | — | 1 | — | — | 2 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | 6 | — | — | — | 8 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 4 | — | — | — | 6 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 3 | — | — | — | 6 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 3 | — | — | — | 3 |
| Hematologic neoplasms | D019337 | — | — | — | 3 | — | — | — | 3 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 1 | — | — | — | 3 |
| Blast crisis | D001752 | — | — | 1 | 2 | — | — | — | 3 |
| T-cell leukemia | D015458 | — | — | — | 2 | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 2 | — | — | — | 2 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | 2 | — | — | — | 2 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell leukemia | D015448 | — | — | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Mediastinal neoplasms | D008479 | — | C38.3 | 1 | — | — | — | — | 1 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | — | — | — | — | 1 |
| Follicular lymphoma | D008224 | — | C82 | 1 | — | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 1 | — | — | — | — | 1 |
| Nephrosis | D009401 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| High-throughput nucleotide sequencing | D059014 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Blinatumomab |
| INN | blinatumomab |
| Description | Blinatumumab (human BiTE) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1742992 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09052 |
| UNII ID | 4FR53SIF3A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Blincyto – Amgen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,980 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blincyto
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,192 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use